Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Official title

A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Overview

Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a very poor prognosis whether treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irradiation or combinations of these modalities. Antiangiogenesis therapy has emerged as a new treatment option in solid malignancies. The frequent delivery of low doses of chemotherapy, referred to as metronomic or antiangiogenic chemotherapy, targets endothelial cells while reducing the toxicity associated with standard dose chemotherapy. The aim of the study is to extend therapy options for children with recurrent or progressive medulloblastoma, ependymoma, ATRT, and CNS tumors of various histologies, for whom no known curative therapy exists, by prolonging survival while maintaining good quality of life. The study will be conducted in independent strata. Stratum I (recurrent medulloblastoma): recently completed (Peyrl, 2023). Stratum II (recurrent ependymoma), III (recurrent ATRT) and V (recurrent CNS tumors of various histologies, patients with exclusion criteria and adult patients): The primary objective is to determine the response rate defined as the percentage of patients with complete response (CR), partial response (PR), stable disease (SD) or lack of recurrence at 6 months after start of antiangiogenic treatment. Stratum IV (recurrent medulloblastoma): To determine whether temozolomide, irinotecan, bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide ivt, cytarabine ivt can increase the response rate after 6 months of treatment, compared with etoposid, cyclophosphamide, bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide ivt, cytarabine ivt. Additionally, PFS, OS, toxicity, QoL, performance status, predictive and prognostic markers will be examined. In stratum II and III, the study will follow an open label, single arm phase 2 design, and an open label randomized two-arm phase 2 design in Stratum IV, and the exploratory Stratum V.

Interventions

• Drug Bevacizumab
  10mg/kg, intravenous (iv), biweekly, 1 year
• Drug Thalidomide
  3mg/kg, oral, daily, 1 year
• Drug Celecoxib
  50-400mg, oral bid, daily, 1 year
• Drug Fenofibric acid
  90mg/m2, oral, daily, 1 year
• Drug Etoposide
  35-50 mg/m2, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
• Drug Cyclophosphamide
  2.5mg/kg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
• Drug Etoposide phosphate
  0.5mg, intrathecal, day 1-5, every four weeks, alternating with intrathecal liposomal cytarabine, 1 year
• Drug Cytarabine
  16-30mg, intrathecal, twice weekly for two weeks out of every four weeks, alternating with intrathecal etoposide phosphate, 1 year
• Drug Temozolomide (TMZ)
  Stratum IV; 150mg/m2, day 1-5 every four weeks
• Drug Irinotecan
  Stratum IV; 50mg/m2, day 1-5 every four weeks

Primary outcome measures

• Efficacy [Time frame: 8 years]

Secondary outcome measures (7)

• Overall survival rate [Time frame: 8 years]
• Progression free survival rate [Time frame: 8 years]
• Toxicity [Time frame: 8 years]
• Feasibility [Time frame: 6 years]
• Quality of life [Time frame: 8 years]
• Prognostic factors [Time frame: 8 years]
• Angiogenic factors [Time frame: 8 years]

Eligibility criteria

Inclusion criteria for patients Stratum I: Relapsed or progressive medulloblastoma - completed Stratum II: Relapsed or progressive ependymoma (at least one site of untreated recurrent disease) Stratum III: Relapsed or progressive ATRT (at least one site of untreated recurrent disease) Stratum IV: Relapsed or progressive medulloblastoma (at least one site of untreated recurrent disease) Stratum V: Relapsed or progressive CNS tumor of various histologies or patients with exclusion criteria or adult patients (explorative) Histological confirmation at diagnosis or relapse Stratum IV: Confirmation of the medulloblastoma group by methylation; IDAT (Intensity Data; raw data of methylation array) Female or male, aged from 0 to <20 years (at time of original diagnosis) Participants must have normal organ and bone marrow function (ALT <5x institutional upper limit of normal, creatinine <1.5x institutional upper limit of normal for age, WBC >1000/mm3, platelets > 20,000/mm3. Patients with values less than WBC 2000/mm3 or platelets 50,000/mm3 will require initiation of treatment with etoposide and cyclophosphamide at a lower starting dose as defined within the protocol Karnofsky performance status ≥50. For infants and children less than 12 years of age, the Lansky play scale ≥50% will be used Written informed consent of patients and / or legal guardian

Exclusion criteria for patients VP- or subdural peritoneal shunt dependency (can be included in Stratum V) Prior treatment with temozolomide/irinotecan (can be included in Stratum V) Active infection, pregnancy or breast feeding Treatment for current relapse (surgery may be performed before MEMMAT treatment; patients with sites of disease not irradiated are still eligible for the protocol) Known hypersensitivity to any of the drugs in the protocol Active peptic ulcer Any significant cardiovascular disease not controlled by standard therapy e.g. systemic hypertension Anticipation of the need for major elective surgery during the course of the study treatment Any disease or condition that contraindicates the use of the study medication/treatment or places the patient at an unacceptable risk of experiencing treatment-related complications Non-healing surgical wound A bone fracture that has not satisfactorily healed

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

Sweden · 6 centers

• Sahlgrenska Universitetssjukhuset — Gothenburg
• Universitetssjukhuset Linköping — Linköping
• Skånes universitetssjukhus — Lund
• Karolinska University Hospital — Stockholm
• Norrlands Universitetssjukhus — Umeå
• Akademiska sjukhuset — Uppsala

Austria · 5 centers

• Medical University of Graz — Graz
• Medical University of Innsbruck — Innsbruck
• Kepler Universitätsklinikum Med Campus IV — Linz
• Salzburger Universitätsklinikum — Salzburg
• Medical University of Vienna — Vienna

United States · 4 centers

• Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago
• Dana-Farber Cancer Institute and Boston Children's Hospital — Boston
• Helen DeVos Children's Hospital — Grand Rapids
• Dell Children's Medical Group SFC-HEM/ONC — Austin

Czechia · 2 centers

• University Hospital Brno — Brno
• Motol University Hospital Prague — Prague

France · 2 centers

• Centre Oscar Lambret — Lille
• Centre Léon Bérard — Lyon

Denmark · 1 center

• University hospital Rigshospitalet — Copenhagen

Norway · 1 center

• Onkologisk-hematologisk seksjon Barneklinikken Haukeland universitetssjukehus — Bergen

Spain · 1 center

• Hospital Infantil Universitario Nino Jesus — Madrid

Publications

• Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, Nysom K, Torsvik I, Chi SN, Perwein T, Jones N, Holm S, Nyman P, Morse H, Oberg A, Weiler-Wichtl L, Leiss U, Haberler C, Schmook MT, Mayr L, Dieckmann K, Kool M, Gojo J, Azizi AA, Andre N, Kieran M, Slavc I. Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Tr PMID 37883081
• Slavc I, Mayr L, Stepien N, Gojo J, Aliotti Lippolis M, Azizi AA, Chocholous M, Baumgartner A, Hedrich CS, Holm S, Sehested A, Leblond P, Dieckmann K, Haberler C, Czech T, Kool M, Peyrl A. Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a "MEMMAT-like" Metronomic Antiangiogenic Approach. Cancers (Basel). 2022 Oct 19;14(20):5128. doi: 10.3390/cancers14205128. PMID 36291912

Identifiers

NCT: NCT01356290 · MUV-MEMMAT-01

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗